CSIMarket
 


Cytokinetics Incorporated  (CYTK)
Other Ticker:  
 
 

CYTK's Capital Expenditures Growth by Quarter and Year

Cytokinetics Incorporated's Capital Expenditures results by quarter and year




CYTK Capital Expenditures (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 3.21 17.75 6.56
III Quarter September 0.22 6.33 15.70 2.59
II Quarter June 0.72 0.86 8.79 0.86
I Quarter March 0.40 0.94 6.63 1.04
FY   1.34 11.34 48.87 11.05



CYTK Capital Expenditures third quarter 2023 Y/Y Growth Comment
Cytokinetics Incorporated reported drop in Capital Expenditures in the third quarter 2023 by -96.52% to $ 0.22 millions, from the same quarter in 2022.
The fall in the third quarter 2023 Cytokinetics Incorporated's Capital Expenditures compares unfavorably to the Company's average Capital Expenditures doubling of 116.71%.

Looking into third quarter 2023 results within Major Pharmaceutical Preparations industry 31 other companies have achieved higher Capital Expenditures growth. While Cytokinetics Incorporated' s Capital Expenditures meltdown of -96.52% ranks overall at the positon no. 877 in the third quarter 2023.




CYTK Capital Expenditures ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -81.92 % 170.58 % 400.76 %
III Quarter September -96.52 % -59.68 % 506.18 % 156.44 %
II Quarter June -16.28 % -90.22 % 922.09 % 1620 %
I Quarter March -57.45 % -85.82 % 537.5 % 300 %
FY   - -76.8 % 342.26 % 320.15 %

Financial Statements
Cytokinetics Incorporated's third quarter 2023 Capital Expenditures $ 0.22 millions CYTK's Income Statement
Cytokinetics Incorporated's third quarter 2022 Capital Expenditures $ 6.33 millions Quarterly CYTK's Income Statement
New: More CYTK's historic Capital Expenditures Growth >>


CYTK Capital Expenditures (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -49.29 % 13.06 % 153.28 %
III Quarter September -69.44 % 636.05 % 78.61 % 201.16 %
II Quarter June 80 % -8.51 % 32.58 % -17.31 %
I Quarter March -87.54 % -94.7 % 1.07 % -20.61 %
FY (Year on Year)   - -76.8 % 342.26 % 320.15 %




Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #102
Overall #877

Capital Expenditures Y/Y Growth Statistics
High Average Low
549.2 % 116.71 % -82.44 %
(Sep 30 2021)   (Sep 30 2023)
Capital Expenditures third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #32
Healthcare Sector #102
Overall #877
Capital Expenditures Y/Y Growth Statistics
High Average Low
549.2 % 116.71 % -82.44 %
(Sep 30 2021)   (Sep 30 2023)

Capital Expenditures by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Cytokinetics Incorporated's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
1912 % 159.83 % -100 %
(Sep 30 2019)  


CYTK's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Cytokinetics Incorporated disclosed fall in Capital Expenditures from the second quarter by -69.44% to $ 0.22 millions, from $ 0.72 millions declared a quarter before.

Some periodic factors which commonly energize III. Quarter 2023 performance, could not salvage the III. Quarter for the Cytokinetics Incorporated, Archie  Davies, Healthcare sector advisor situated in Glasgow pointed out, he identified further challenges ahead for Cytokinetics Incorporated.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cytokinetics Incorporated's Capital Expenditures growth quarter on quarter, overall rank is 1286.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #150
Overall #1286
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #48
Healthcare Sector #150
Overall #1286
Capital Expenditures Q/Q Growth Statistics
High Average Low
1912 % 159.83 % -100 %
(Sep 30 2019)  


CYTK's III. Quarter Q/Q Capital Expenditures Comment
In the III. Quarter 2023 Cytokinetics Incorporated disclosed fall in Capital Expenditures from the second quarter by -69.44% to $ 0.22 millions, from $ 0.72 millions released in the previous reporting period.

Some seasonal circumstance which commonly fuel III. Quarter 2023 results, have not recover the III. Quarter for the Cytokinetics Incorporated, Archie  Davies, Healthcare sector advisor situated in Glasgow wrote, he detected new headwinds ahead for the Major Pharmaceutical Preparations's company and wrote that average sequential Capital Expenditures growth is at 159.83% for the Major Pharmaceutical Preparations's company.

Within Major Pharmaceutical Preparations industry 47 other companies have achieved higher Capital Expenditures quarter on quarter growth. While Cytokinetics Incorporated's Capital Expenditures growth quarter on quarter, overall rank is 1286.


Cytokinetics Incorporated's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Capital Expenditures 12 Months Ending $ 4.54 $ 10.66 $ 10.80 $ 11.34 $ 25.88
Y / Y Capital Expenditures Growth (TTM) -82.44 % -69.78 % -75 % -76.81 % -31.29 %
Year on Year Capital Expenditures Growth Overall Ranking # 900 # 208 # 55 # 66 # 2049
Seqeuential Capital Expenditures Change (TTM) -57.35 % -1.3 % -4.76 % -56.21 % -26.58 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 1890 # 650 # 856 # 986 # 2508




Cumulative Capital Expenditures growth Comment
Cytokinetics Incorporated's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -82.44% year on year, at Sep 30 2023 compare to the -69.78% decrease at Jun 30 2023. If the Cytokinetics Incorporated's fiscal year would end at Sep 30 2023, annual Capital Expenditures would be $5 millions.

In the Healthcare sector 106 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 208 to 900.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
549.2 %
116.71 %
-82.44 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 107
Overall # 900

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
549.2 %
116.71 %
-82.44 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 270
S&P 500 # 1890
Cumulative Capital Expenditures growth Comment
Cytokinetics Incorporated's cumulative 12 months Capital Expenditures continue to drop, but on the faster rate at -82.44% year on year, at Sep 30 2023 compare to the -69.78% decrease at Jun 30 2023. If the Cytokinetics Incorporated's fiscal year would end at Sep 30 2023, annual Capital Expenditures would be $5 millions.

In the Healthcare sector 106 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Capital Expenditures growth total ranking has deteriorated compare to previous quarter from 208 to 900.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
549.2 %
116.71 %
-82.44 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 90
Healthcare Sector # 107
Overall # 900

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
549.2 %
116.71 %
-82.44 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 90
Sector # 270
S&P 500 # 1890




Other Capital Expenditures Growth
Major Pharmaceutical Preparations Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CYTK's Capital Expenditures Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CYTK's Competitors
Capital Expenditures Growth for Cytokinetics Incorporated's Suppliers
Capital Expenditures Growth for CYTK's Customers

You may also want to know
CYTK's Annual Growth Rates CYTK's Profitability Ratios CYTK's Asset Turnover Ratio CYTK's Dividend Growth
CYTK's Roe CYTK's Valuation Ratios CYTK's Financial Strength Ratios CYTK's Dividend Payout Ratio
CYTK's Roa CYTK's Inventory Turnover Ratio CYTK's Growth Rates CYTK's Dividend Comparisons



Companies with similar Capital Expenditures drop for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Sep 30 2023
Encompass Health Corporation-0.54%$ -0.542 millions
Myriad Genetics Inc -1.13%$ -1.130 millions
Opgen Inc -1.22%$ -1.220 millions
Avantor Inc -3.33%$ -3.333 millions
United Therapeutics Corporation-4.51%$ -4.506 millions
Enanta Pharmaceuticals Inc-4.80%$ -4.802 millions
Davita Inc -5.46%$ -5.463 millions
Science 37 Holdings Inc -5.63%$ -5.630 millions
Cutera Inc -5.71%$ -5.708 millions
Zoetis Inc -5.84%$ -5.844 millions
U S Physical Therapy Inc-6.25%$ -6.248 millions
Generation Bio Co -6.30%$ -6.298 millions
Ngm Biopharmaceuticals Inc -6.45%$ -6.452 millions
Becton Dickinson And Company-6.67%$ -6.667 millions
3m Company-6.90%$ -6.897 millions
Apyx Medical Corporation-7.45%$ -7.447 millions
Edwards Lifesciences Corporation-7.68%$ -7.679 millions
Viatris Inc -7.70%$ -7.700 millions
Luna Innovations Inc-8.23%$ -8.232 millions
Nevro Corp -8.38%$ -8.377 millions
Shockwave Medical Inc -8.65%$ -8.649 millions
Sonendo Inc -8.86%$ -8.861 millions
Charles River Laboratories International inc -8.90%$ -8.904 millions
Nautilus Biotechnology Inc -9.24%$ -9.242 millions
Harvard Bioscience Inc-9.28%$ -9.276 millions
Fulgent Genetics Inc -9.42%$ -9.420 millions
Idexx Laboratories Inc-9.53%$ -9.529 millions
Sage Therapeutics Inc -9.89%$ -9.890 millions
Caredx Inc -10.40%$ -10.400 millions
Quest Diagnostics Inc-11.02%$ -11.017 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com